People: Angiotech Pharmaceuticals, Inc. (ANPI.O)

ANPI.O on Nasdaq

1.03USD
9 Feb 2010
Price Change (% chg)

$-0.03 (-2.83%)
Prev Close
$1.03
Open
--
Day's High
$1.07
Day's Low
$1.03
Volume
223,463
Avg. Vol
275,646
52-wk High
$2.94
52-wk Low
$0.26

view people for:

Summary

Name Age Since Current Position
Howard, David 59 2002 Chairman of the Board
Hunter, William 46 2002 President, Chief Executive Officer, Director
Bailey, K.Thomas 40 2005 Chief Financial Officer
Dent, Jay 50 2008 Senior Vice President - Finance
McMasters, David 49 2004 Senior Vice President - Legal and General Counsel
Neske, Tammy 38 2008 Senior Vice President - Human Resources
Chen, Jonathan 34 2008 Senior Vice President - Business Development & Financial Strategy
Gross, Jeffrey 45 2008 Senior Vice President - Research and Development
Diaz, Victor 48 Senior Vice President - Global Manufacturing and Supply Chain Management
Avelar, Rui 47 2005 Chief Medical Officer
Willms, Arthur 69 2004 Director
Brown, Edward 45 2004 Director
Brege, Laura 51 2007 Director
McKinnell, Henry 66 2008 Director
» Insider Trading

Biographies

Name Description
Howard, David Mr. David T. Howard is Chairman of the Board of Angiotech Pharmaceuticals, Inc. since September 2002. He joined the Board of Directors in March 2000. Mr. Howard is a director of SemBioSys Genetics, Inc. and Via Pharmaceuticals, Inc. Previously, he was Chair of the Board, President and CEO of SCOLR, Inc., a biopharmaceutical company located in Redmond, Washington. Prior to this, Mr. Howard served as President and Chief Operating Officer of Novopharm International, Inc. of Toronto, Ontario and President of Novopharm USA, Inc. Mr. Howard’s industry experience includes operational and strategic positions with Boehringer Mannheim Canada, where he was Vice President Pharmaceuticals, and Rhône-Poulenc Pharma in Montreal and Paris, where he was Vice-President Sales and Marketing.
Hunter, William Dr. William Hunter M.D., is a founder, President, Chief Executive Officer, Director of Angiotech Pharmaceuticals, Inc. He has been Chief Executive Officer of the Company since 1997, and has been a member of the Company’s scientific and management teams since its inception. He serves as a director of Cardiome Pharma, Corp. and is Chair of the Board of Neuromed Pharmaceuticals, Inc. Dr. Hunter is also an advisory board member for the Biotechnology MBA Program at the University of Western Ontario’s Ivey School of Business and an active member of the Government of British Columbia Premier’s Technology Council. Dr. Hunter has been honored with many awards including, most recently, the 2005 BC Innovation Council’s Cecil Green Award for Science and Technology Entrepreneurship and the 2005 Canadian Venture Capital Association’s Entrepreneur of the Year. He received his Bachelor of Science Degree from McGill University, Montreal in 1985 and his Masters of Science and Doctor of Medicine Degree from the University of British Columbia in 1989 and 1992, respectively.
Bailey, K.Thomas Mr. K. Thomas Bailey is Chief Financial Officer of Angiotech Pharmaceuticals, Inc. Since January 2004 to December 2005—Vice President, Business Development, the Company.
Dent, Jay Mr. Jay Dent is Senior Vice President - Finance of Angiotech Pharmaceuticals, Inc. since December 2006 to present. Since October 2005 to November 2006—Vice President, Finance & Accounting, the Company; May 2001 to September 2005—Controller, Ballard Power Systems, Inc.
McMasters, David Mr. David D. McMasters is Senior Vice President - Legal and General Counsel of Angiotech Pharmaceuticals, Inc.
Neske, Tammy Mr. Tammy Neske is Senior Vice President - Human Resources of Angiotech Pharmaceuticals, Inc. from January 2008 to present. Since January 2007 to January 2008—Vice President, Human Resources, the Company; July 2005 to January 2007—Director, Corporate Development, the Company; 2000 to 2005—Manager, Employment and Compensation, Ballard Power Systems, Inc.
Chen, Jonathan Mr. Jonathan W. Chen is Senior Vice President - Business Development & Financial Strategy of Angiotech Pharmaceuticals, Inc. Since September 2005 to January 2008—Vice President, Business Development & Financial Strategy, the Company; September 2000 to May 2005—Investment Banker, Credit Suisse First Boston.
Gross, Jeffrey Mr. Jeffrey Gross is Senior Vice President - Research and Development of Angiotech Pharmaceuticals, Inc. Since Jul 2007 - Sep 2008, Vice President, Engineering, Research and Development, the Company; 2004 - 2007, Group Director, Biologics Research & Development, Medtronic Spinal & Biologics; 2002 - 2004, Group Director, R&D and Tissue Bank Operations, Medtronic Sofamor Danek.
Diaz, Victor Mr. Victor Diaz is Senior Vice President - Global Manufacturing and Supply Chain Management of Angiotech Pharmaceuticals, Inc. form 2007 to present. Since 2003 to 2006—Vice President, Global Operations, Teleflex Medical.
Avelar, Rui Dr. Rui Avelar M.D., is Chief Medical Officer of Angiotech Pharmaceuticals, Inc. Since January 2004 to December 2005 - Senior Vice President, Medical Affairs & Communications, the Company.
Willms, Arthur Mr. Arthur H. Willms is Director of Angiotech Pharmaceuticals, Inc. Mr. Willms is a Director and retired President and Chief Operating Officer of Westcoast Energy, Inc. where he held senior executive positions for 24 years. Mr. Willms’ other directorships include Pacific Northern Gas Ltd., BC Lotteries Corp. and Pristine Power Inc. He is also the Chair of the Board for the Vancouver Symphony Orchestra. Mr. Willms has been a lecturer in Economics at the University of Calgary and holds a Bachelor of Arts Degree in Education, a Bachelor of Science Degree in Mathematics, and a Masters Degree in Economics from the University of Calgary. Mr. Willms is a member of two audit committees and is the chair of one of these committees.
Brown, Edward Mr. Edward M. Brown is a Director of Angiotech Pharmaceuticals, Inc. Mr. Brown is a Managing Director of TPG Growth, a private equity firm, where he focuses on private equity investments in healthcare companies. Prior to joining TPG Growth, Mr. Brown was a co-founder of Healthcare Investment Partners (“HIP”), a private equity firm focused exclusively on healthcare investments. Before HIP, Mr. Brown was a Managing Director in the Healthcare Group of Credit Suisse First Boston, an investment bank, where he led the firm’s West Coast healthcare effort and was one of the senior partners responsible for the firm’s global life sciences practice. Mr. Brown has over 19 years of experience as a financial advisor and investor in the healthcare industry. Mr. Brown also serves on the Board of Directors of Replidyne, Inc. Mr. Brown graduated Phi Beta Kappa, Magna Cum Laude with High Honors from Middlebury College with a B.A. Degree in English and received his MBA degree from Anderson Graduate School of Management at UCLA.
Brege, Laura Ms. Laura Brege is Director of Angiotech Pharmaceuticals, Inc. effective August 2nd 2007. Ms. Brege is currently Executive Vice President and Chief Operating Officer at Onyx Pharmaceuticals, Inc., where she is responsible for Sales and Marketing, Medical Affairs, Legal, Business Development, and Compliance. Onyx Pharmaceuticals is focused on developing and commercializing innovative cancer treatments. Prior to joining Onyx Pharmaceuticals, Ms. Brege was a General Partner at Red Rock Management, a venture capital firm specializing in early stage financing for technology companies. Prior to her work at Red Rock Management, she was the Senior Vice President and Chief Financial Officer at COR Therapeutics, a biotechnology company that specialized in drug therapies for cardiovascular disease. While at COR, Ms. Brege was instrumental in helping the company grow from a research and development start-up to an operations-based enterprise with a commercialized product. Before joining COR, Ms. Brege was Vice President and Chief Financial Officer at Flextronics, a multi-billion dollar electronics manufacturer. She was also Vice President and Treasurer of The Cooper Companies, a Fortune 500 diversified company with operations worldwide. Ms. Brege earned her undergraduate degree from Ohio University and has an MBA from the University of Chicago.
McKinnell, Henry Dr. Henry McKinnell Jr., Ph.D., a is Director of Angiotech Pharmaceuticals, Inc. Dr. McKinnell is the Chairman of the Accordia Global Health Foundation, an organization he co-founded to strengthen academic medical centers in Africa to help in the fight against infectious diseases. He is Chairman of the Governance and Compensation Committee, is a member of the Audit Committee and serves as the Lead Independent Director of the Board of Directors of Moody’s Corporation. Dr. McKinnell is the former Chief Executive Officer and former Chairman of the Board of Directors of Pfizer Inc. Dr. McKinnell joined Pfizer in 1971 in Tokyo and over the years, held positions of increasing responsibility around the world, including service as President of Pfizer Asia. In 1984, Dr. McKinnell relocated to New York, where he served as Vice President-Strategic Planning, Chief Financial Officer, President- Pfizer Medical Device Group, President-Pfizer Pharmaceuticals Group, and President and Chief Operating Officer. He was named Chairman and Chief Executive officer in 2001 and served in this role until his retirement in the second half of 2006. Dr. McKinnell is the Chairman Emeritus of the Business Roundtable, an association of the CEOs of America’s largest companies, the Pharmaceutical Research Manufacturers Association, the Food and Drug Law Institute, and the Medical Device Manufacturers Association. He has also served as vice chairman of the World Economic Forum, as a member of the WEF Foundation Board of Trustees, and served on the President’s Advisory Council on HIV/AIDS. Dr. McKinnell holds a Bachelor’s Degree in business from the University of British Columbia, and M.B.A. and Ph.D. degrees from the Stanford University Graduate School of Business.

Basic Compensation

Name Fiscal Year Total
Howard, David --
Hunter, William 1,281,370
Bailey, K.Thomas 859,164
Dent, Jay --
McMasters, David 909,278
Neske, Tammy --
Chen, Jonathan --
Gross, Jeffrey --
Diaz, Victor --
Avelar, Rui 744,478
Willms, Arthur --
Brown, Edward --
Brege, Laura --
McKinnell, Henry --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Howard, David 0 0
Hunter, William 2,300,000 14,585,780
Bailey, K.Thomas 0 0
Dent, Jay 0 0
McMasters, David 1,000,000 3,700,632
Neske, Tammy 0 0
Chen, Jonathan 0 0
Gross, Jeffrey 0 0
Diaz, Victor 0 0
Avelar, Rui 443,809 1,782,438
Willms, Arthur 0 0
Brown, Edward 0 0
Brege, Laura 0 0
McKinnell, Henry 0 0

Insider Trading

Name Shares Traded Price
HUNTER WILLIAM L 3,000 $1.30
HUNTER WILLIAM L 11,100 $1.32
HUNTER WILLIAM L 1,500 $1.31
HUNTER WILLIAM L 20,000 $1.75
HUNTER WILLIAM L 2,200 $1.74
HUNTER WILLIAM L 21,600 $1.74
HUNTER WILLIAM L 300 $1.73
HUNTER WILLIAM L 5,400 $1.73
GROSS JEFFREY M 6,000 $1.68
BAILEY K THOMAS 1,100 $1.69
BAILEY K THOMAS 13,900 $1.70
BAILEY K THOMAS 15,000 $1.64
NESKE TAMMY 3,000 $1.91
GROSS JEFFREY M 1,500 $1.72
NESKE TAMMY 3,300 $1.90
GROSS JEFFREY M 2,000 $1.80
DENT JAY BERNARD 6,000 $1.96
DENT JAY BERNARD 8,000 $1.95
DENT JAY BERNARD 2,700 $1.94
CHEN JONATHAN W 5,200 $1.76
WILLMS ARTHUR H 25,000 $1.75
CHEN JONATHAN W 1,100 $1.78
CHEN JONATHAN W 2,900 $1.77
CHEN JONATHAN W 1,900 $1.78
RICHARDSON HARTLEY T 10,000 $0.21
» Full list on Insider Trading
view people for: